ARTICLE | Product Development
Tracking the rise and fall of next-generation checkpoint targets for cancer
BioCentury’s analysis of next-generation checkpoint targets finds three that are gathering steam
October 19, 2019 1:31 AM UTC
Updated on Oct 26, 2019 at 12:15 AM UTC
As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead.
BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field turned to new targets that would extend efficacy beyond the subset of patients who respond to PD-1...
BCIQ Company Profiles
BCIQ Target Profiles
Carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 (CEACAM1) (CD66a)
Glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) (TNFRSF18)
Inducible T cell co-stimulator (ICOS)
Lymphocyte-activation gene 3 (LAG3) (CD223)
Poliovirus receptor related immunoglobulin domain containing (PVRIG) (CD112R)